نتائج البحث

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

• Authors : Janssen Scientific Affairs, LLC

• Source: A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

تفاصيل العنوان

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

• Source: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple MyelomaChari A, Munder M, Weisel K, Jenner M, Bygrave C, Petrucci

تفاصيل العنوان

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

• Source: A Personalized Vaccine for the Immune Prevention of Multiple Myeloma

تفاصيل العنوان

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

• Source: Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple MyelomaLonial S, Jacobus S, Fonseca

تفاصيل العنوان

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

• Authors : Keymed Biosciences Co.Ltd

• Source: A Prospective, Multi-center, Single-arm Clinical Trial of BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

تفاصيل العنوان

A Real-world Study in Participants With Smoldering Multiple Myeloma

• Source: Smoldering Pathway Assessment Real-World Knowledge (SPARK) Study-Retrospective Observational, Non-interventional Chart Review Study in

تفاصيل العنوان

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

• Source: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma

تفاصيل العنوان

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

• Authors : National Cancer Institute (NCI)

• Source: Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple MyelomaManasanch EE, Han G,

تفاصيل العنوان

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma (LINKER-MGUS1)

• Source: Phase 2 Dose-Ranging and Interception Study of Linvoseltamab in Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering

تفاصيل العنوان

A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma

• Source: A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma (BELLA)

تفاصيل العنوان